{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:14:49Z","timestamp":1788671689288,"version":"build-2803163510"},"reference-count":82,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["954992"],"award-info":[{"award-number":["954992"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"award":["954992"],"award-info":[{"award-number":["954992"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca","doi-asserted-by":"publisher","award":["IG18495"],"award-info":[{"award-number":["IG18495"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca","doi-asserted-by":"publisher","award":["IG24345"],"award-info":[{"award-number":["IG24345"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015550","name":"Ministry of Health","doi-asserted-by":"publisher","award":["PE-2011-02351866"],"award-info":[{"award-number":["PE-2011-02351866"]}],"id":[{"id":"10.13039\/501100015550","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAPSTONE-ETN H2020 Early Stage Researcher"},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/041g7jm83","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Cancer immunotherapy has transformed the treatment of multiple malignancies; however, primary and acquired resistance remain major clinical challenges. Because effective immune recognition depends on the repertoire of peptides presented by major histocompatibility complex class I (MHC-I) molecules, increasing attention has focused on the antigen processing and presentation pathway as a therapeutic target to enhance tumor immunogenicity. Among its key regulators, the endoplasmic reticulum (ER) aminopeptidases ERAP1 and ERAP2 shape the MHC-I immunopeptidome by trimming peptide precursors before antigen presentation. Beyond this canonical function, accumulating evidence indicates that ERAP aminopeptidases are multifunctional proteins involved in inflammation, angiogenesis, ER stress responses, cell migration, and tumor-intrinsic signaling. These moonlighting activities suggest that ERAP enzymes influence cancer progression through both immune-dependent and immune-independent mechanisms. Recent advances in medicinal chemistry have enabled the development of selective ERAP1 inhibitors, leading to the first clinical evaluation of this therapeutic strategy and providing early clinical evidence that pharmacological modulation of antigen processing may complement existing immunotherapies. In this review, we summarize the multiple functions of ERAP aminopeptidases in cancer, discuss their role in regulating adaptive and innate immune responses, and highlight emerging therapeutic strategies and future challenges for exploiting ERAP-targeted interventions in precision immuno-oncology.<\/jats:p>","DOI":"10.3390\/cells15171609","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:50:44Z","timestamp":1788529844000},"page":"1609","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moonlighting ERAP Aminopeptidases in Cancer: Beyond Antigen Processing"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5088-1757","authenticated-orcid":false,"given":"Paula","family":"Gragera","sequence":"first","affiliation":[{"name":"Ospedale Pediatrico Bambino Ges\u00f9 IRCCS, 00146 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5005-5910","authenticated-orcid":false,"given":"Valentina","family":"Scaldaferri","sequence":"additional","affiliation":[{"name":"Ospedale Pediatrico Bambino Ges\u00f9 IRCCS, 00146 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-7296","authenticated-orcid":false,"given":"Doriana","family":"Fruci","sequence":"additional","affiliation":[{"name":"Ospedale Pediatrico Bambino Ges\u00f9 IRCCS, 00146 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41568-024-00723-5","article-title":"Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance","volume":"24","author":"Wellhausen","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: Mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.suronc.2019.10.002","article-title":"Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3\u2013T4 non-metastatic gastric cancer","volume":"32","author":"Petrioli","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41590-024-01960-4","article-title":"The complexity of immune evasion mechanisms throughout the metastatic cascade","volume":"25","author":"Haynes","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Galan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"eadh1781","DOI":"10.1126\/sciimmunol.adh1781","article-title":"Innate receptors with high specificity for HLA class I-peptide complexes","volume":"8","author":"Sim","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, S., Tempora, P., Melaiu, O., Lucarini, V., Cifaldi, L., Locatelli, F., and Fruci, D. (2022). Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.948297"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ni1208","article-title":"Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum","volume":"6","author":"Saveanu","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.immuni.2006.09.012","article-title":"ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum","volume":"25","author":"Kanaseki","year":"2006","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/ni860","article-title":"The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8\u20139 residues","volume":"3","author":"York","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17107","DOI":"10.1073\/pnas.0500721102","article-title":"The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a \u201cmolecular ruler\u201d mechanism","volume":"102","author":"Chang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"26709","DOI":"10.1073\/pnas.1912070116","article-title":"Mechanism for antigenic peptide selection by endoplasmic reticulum aminopeptidase 1","volume":"116","author":"Giastas","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nsmb.2021","article-title":"Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1","volume":"18","author":"Nguyen","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/imm.13709","article-title":"Structure-guided discovery of aminopeptidase ERAP1 variants capable of processing antigens with novel PC anchor specificities","volume":"171","author":"Pande","year":"2024","journal-title":"Immunology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature01074","article-title":"ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum","volume":"419","author":"Serwold","year":"2002","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4049\/jimmunol.1302855","article-title":"ERAP1-ERAP2 dimerization increases peptide-trimming efficiency","volume":"193","author":"Evnouchidou","year":"2014","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Martin-Esteban, A., Rodriguez, J.C., Peske, D., Lopez de Castro, J.A., Shastri, N., and Sadegh-Nasseri, S. (2022). The ER Aminopeptidases, ERAP1 and ERAP2, synergize to self-modulate their respective activities. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1066483"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100443","DOI":"10.1016\/j.jbc.2021.100443","article-title":"Common allotypes of ER aminopeptidase 1 have substrate-dependent and highly variable enzymatic properties","volume":"296","author":"Hutchinson","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"BSR20171503","DOI":"10.1042\/BSR20171503","article-title":"The role of polymorphic ERAP1 in autoinflammatory disease","volume":"38","author":"Reeves","year":"2018","journal-title":"Biosci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Andres, A.M., Dennis, M.Y., Kretzschmar, W.W., Cannons, J.L., Lee-Lin, S.Q., Hurle, B., Program, N.C.S., Schwartzberg, P.L., Williamson, S.H., and Bustamante, C.D. (2010). Balancing selection maintains a form of ERAP2 that undergoes nonsense-mediated decay and affects antigen presentation. PLoS Genet., 6.","DOI":"10.1371\/journal.pgen.1001157"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100460","DOI":"10.1016\/j.xgen.2023.100460","article-title":"A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPs","volume":"4","author":"Venema","year":"2024","journal-title":"Cell Genom."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/ng.873","article-title":"Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility","volume":"43","author":"Evans","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Genetic Analysis of Psoriasis Consortium, The Wellcome Trust Case Control Consortium, Strange, A., Capon, F., Spencer, C.C., Knight, J., Weale, M.E., Allen, M.H., Barton, A., and Band, G. (2010). A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet., 42, 985\u2013990.","DOI":"10.1038\/ng.694"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1074\/mcp.RA119.001515","article-title":"Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet\u2019s Disease-associated HLA-B*51 Peptidome","volume":"18","author":"Guasp","year":"2019","journal-title":"Mol. Cell Proteom."},{"key":"ref_29","first-page":"4333","article-title":"Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis","volume":"27","author":"Kuiper","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jhep.2019.01.034","article-title":"ERAP1 allotypes shape the epitope repertoire of virus-specific CD8(+) T cell responses in acute hepatitis C virus infection","volume":"70","author":"Kemming","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Al-Kaabi, M., Deshpande, P., Firth, M., Pavlos, R., Chopra, A., Basiri, H., Currenti, J., Alves, E., Kalams, S., and Fellay, J. (2024). Epistatic interaction between ERAP2 and HLA modulates HIV-1 adaptation and disease outcome in an Australian population. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012359"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1038\/s41598-021-86240-z","article-title":"Genetic association of ERAP1 and ERAP2 with eclampsia and preeclampsia in northeastern Brazilian women","volume":"11","author":"Ferreira","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Adamo, A., Frusteri, C., Pallotta, M.T., Pirali, T., Sartoris, S., and Ugel, S. (2020). Moonlighting Proteins Are Important Players in Cancer Immunology. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.613069"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: From vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2003-12-4260","article-title":"Puromycin-insensitive leucyl-specific aminopeptidase (PILSAP) binds and catalyzes PDK1, allowing VEGF-stimulated activation of S6K for endothelial cell proliferation and angiogenesis","volume":"104","author":"Yamazaki","year":"2004","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V99.9.3241","article-title":"A mouse orthologue of puromycin-insensitive leucyl-specific aminopeptidase is expressed in endothelial cells and plays an important role in angiogenesis","volume":"99","author":"Miyashita","year":"2002","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Saulle, I., Limanaqi, F., Garziano, M., Murno, M.L., Artusa, V., Strizzi, S., Giovarelli, M., Schulte, C., Aiello, J., and Clerici, M. (2024). Impact of endoplasmic reticulum aminopeptidases 1 (ERAP1) and 2 (ERAP2) on neutrophil cellular functions. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1506216"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"61698","DOI":"10.18632\/oncotarget.18680","article-title":"Endoplasmic reticulum aminopeptidase 2 involvement in metastasis of oral cavity squamous cell carcinoma discovered by proteome profiling of primary cancer cells","volume":"8","author":"Kuo","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1038\/s41467-019-11093-0","article-title":"ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of betaTrCP","volume":"10","author":"Bufalieri","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ymthe.2025.10.036","article-title":"Discovery of a new selective ERAP1 inhibitor for Hedgehog-dependent cancer treatment","volume":"34","author":"Bufalieri","year":"2026","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pan.2021.09.012","article-title":"ERAP2 is a novel target involved in autophagy and activation of pancreatic stellate cells via UPR signaling pathway","volume":"22","author":"Guan","year":"2022","journal-title":"Pancreatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/art.42327","article-title":"Paradoxical Effects of Endoplasmic Reticulum Aminopeptidase 1 Deficiency on HLA-B27 and Its Role as an Epistatic Modifier in Experimental Spondyloarthritis","volume":"75","author":"Tran","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.jbchem.a022812","article-title":"Characterization of recombinant human adipocyte-derived leucine aminopeptidase expressed in Chinese hamster ovary cells","volume":"128","author":"Hattori","year":"2000","journal-title":"J. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"32275","DOI":"10.1074\/jbc.M305076200","article-title":"Human leukocyte-derived arginine aminopeptidase. The third member of the oxytocinase subfamily of aminopeptidases","volume":"278","author":"Tanioka","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.molcel.2015.04.008","article-title":"ERp44 Exerts Redox-Dependent Control of Blood Pressure at the ER","volume":"58","author":"Hisatsune","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, S., Tempora, P., Lucarini, V., Melaiu, O., Gaspari, S., Algeri, M., and Fruci, D. (2021). ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041705"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mattorre, B., Caristi, S., Donato, S., Volpe, E., Faiella, M., Paiardini, A., Sorrentino, R., and Paladini, F. (2022). A Short ERAP2 That Binds IRAP Is Expressed in Macrophages Independently of Gene Variation. Int. J. Mol. Sci., 23.","DOI":"10.1101\/2022.03.07.483178"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mattorre, B., Tedeschi, V., Paldino, G., Fiorillo, M.T., Paladini, F., and Sorrentino, R. (2022). The emerging multifunctional roles of ERAP1, ERAP2 and IRAP between antigen processing and renin-angiotensin system modulation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1002375"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28677","DOI":"10.1074\/jbc.M300456200","article-title":"An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding","volume":"278","author":"Cui","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.4049\/jimmunol.171.12.6814","article-title":"Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding","volume":"171","author":"Cui","year":"2003","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21906","DOI":"10.1074\/jbc.M111.239111","article-title":"Secretion of endoplasmic reticulum aminopeptidase 1 is involved in the activation of macrophages induced by lipopolysaccharide and interferon-gamma","volume":"286","author":"Goto","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.4049\/jimmunol.1300935","article-title":"TLR-mediated secretion of endoplasmic reticulum aminopeptidase 1 from macrophages","volume":"192","author":"Goto","year":"2014","journal-title":"J. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jb\/mvv001","article-title":"Substrate-dependent nitric oxide synthesis by secreted endoplasmic reticulum aminopeptidase 1 in macrophages","volume":"157","author":"Goto","year":"2015","journal-title":"J. Biochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.bbamcr.2018.03.009","article-title":"Contribution of the exosome-associated form of secreted endoplasmic reticulum aminopeptidase 1 to exosome-mediated macrophage activation","volume":"1865","author":"Goto","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Saulle, I., Ibba, S.V., Torretta, E., Vittori, C., Fenizia, C., Piancone, F., Minisci, D., Lori, E.M., Trabattoni, D., and Gelfi, C. (2019). Endoplasmic Reticulum Associated Aminopeptidase 2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-1 Infection. Front. Immunol., 10, Corrigendum in Front. Immunol.\u00a02019, 10, 2838. https:\/\/doi.org\/10.3389\/fimmu.2019.02838.","DOI":"10.3389\/fimmu.2019.02838"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000368899","article-title":"Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells","volume":"7","author":"Aldhamen","year":"2015","journal-title":"J. Innate Immun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2337\/db21-0857","article-title":"Hepatokine ERAP1 Disturbs Skeletal Muscle Insulin Sensitivity Via Inhibiting USP33-Mediated ADRB2 Deubiquitination","volume":"71","author":"Niu","year":"2022","journal-title":"Diabetes"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/acsmedchemlett.9b00002","article-title":"High-Resolution Crystal Structure of Endoplasmic Reticulum Aminopeptidase 1 with Bound Phosphinic Transition-State Analogue Inhibitor","volume":"10","author":"Giastas","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1021\/acs.jmedchem.4c00840","article-title":"ERAP Inhibitors in Autoimmunity and Immuno-Oncology: Medicinal Chemistry Insights","volume":"67","author":"Fougiaxis","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"19890","DOI":"10.1073\/pnas.1309781110","article-title":"Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses","volume":"110","author":"Zervoudi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"116926","DOI":"10.1016\/j.ejmech.2024.116926","article-title":"First fragment-based screening identifies new chemotypes inhibiting ERAP1-metalloprotease","volume":"280","author":"Fougiaxis","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15358","DOI":"10.1021\/acs.jmedchem.6c00029","article-title":"Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity In Vivo","volume":"69","author":"Tinworth","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_63","first-page":"A583","article-title":"553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition","volume":"9","author":"Joyce","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e202203560","DOI":"10.1002\/anie.202203560","article-title":"Discovery of the First Selective Nanomolar Inhibitors of ERAP2 by Kinetic Target-Guided Synthesis","volume":"61","author":"Camberlein","year":"2022","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"126555","DOI":"10.1016\/j.ijpharm.2026.126555","article-title":"ERAP2 inhibitor -incorporated nanofibers: Characterization and biological assessment","volume":"690","author":"Vasconcelos","year":"2026","journal-title":"Int. J. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/0008-5472.CAN-10-3326","article-title":"Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing","volume":"71","author":"Cifaldi","year":"2011","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4049\/jimmunol.1300598","article-title":"Naturally occurring ERAP1 haplotypes encode functionally distinct alleles with fine substrate specificity","volume":"191","author":"Reeves","year":"2013","journal-title":"J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00262-019-02358-0","article-title":"Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1)","volume":"68","author":"Koumantou","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13046-024-03180-y","article-title":"Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma","volume":"43","author":"Tempora","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Temponeras, I., Stamatakis, G., Samiotaki, M., Georgiadis, D., Pratsinis, H., Panayotou, G., and Stratikos, E. (2022). ERAP2 Inhibition Induces Cell-Surface Presentation by MOLT-4 Leukemia Cancer Cells of Many Novel and Potentially Antigenic Peptides. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031913"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100964","DOI":"10.1016\/j.mcpro.2025.100964","article-title":"ERAP1 Activity Modulates the Immunopeptidome but Also Affects the Proteome, Metabolism, and Stress Responses in Cancer Cells","volume":"24","author":"Nikopaschou","year":"2025","journal-title":"Mol. Cell Proteom."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e2350449","DOI":"10.1002\/eji.202350449","article-title":"Distinct modulation of cellular immunopeptidome by the allosteric regulatory site of ER aminopeptidase 1","volume":"53","author":"Temponeras","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/0008-5472.CAN-14-1643","article-title":"ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors","volume":"75","author":"Cifaldi","year":"2015","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, S., D\u2019Alicandro, V., Compagnone, M., Tempora, P., Guida, G., Romania, P., Lucarini, V., Melaiu, O., Falco, M., and Algeri, M. (2021). ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.778103"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.immuni.2024.10.013","article-title":"Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint","volume":"57","author":"Tsao","year":"2024","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1200\/JCO.2024.42.16_suppl.2589","article-title":"EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies","volume":"42","author":"Lillie","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2026.44.16_suppl.2500","article-title":"EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti\u2013PD-1 resistance or MSS-CRC","volume":"44","author":"Thistlethwaite","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.ymthe.2021.06.010","article-title":"Aptamers: Cutting edge of cancer therapies","volume":"29","author":"Shigdar","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1609\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:33:00Z","timestamp":1788669180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":82,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cells15171609"],"URL":"https:\/\/doi.org\/10.3390\/cells15171609","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}